CRL
HealthcareCharles River Laboratories International, Inc.
Key Drivers
- Strong FCF
- Recent EBITDA loss
- Elevated leverage
AIAI Summary
CRL's investment case shifts from a macro‑dependent recovery to an execution story—its sizable FCF and active divestitures/capex redeployment can drive upside only if management delivers the targeted ~$225M+ savings, successfully reinvests in cell/gene CDMO and NAMs, and stabilizes bookings. Key downside is execution and overhang risk: failure to hit cost saves, convert bookings, or contain the Cambodia NHP/legal issues would amplify leverage sensitivity and likely compress the premium multiple.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong FCF
- •Recent EBITDA loss
- •Elevated leverage
CRL shows solid revenue, gross margin and strong annual free cash flow but recent quarterly operating losses, negative net income and elevated leverage create meaningful near-term risk.
Price Behavior
Key Price Behavior Insights:
- •Near last-month low
- •Failed SMA retake
- •Lower highs forming
Stock is in a clear short-term downtrend, trading near last month's low (~$152) after a ~9% decline from $168.92, with resistance at $167–169 and $181.32 required to confirm a reversal.
~9% drop from $168.92 on 2026-02-20 to $153.60 on 2026-03-20
Sentiment & News
Key News Insights:
- •Divestitures & guidance
- •Institutional buying
- •Mixed market reaction
Charles River is reshaping its portfolio with divestitures that raised 2026 profit guidance, drew institutional buyers and analyst focus, but the stock remains weak near term.
Portfolio cleanup and clearer guidance should support longer-term earnings visibility and investor confidence, but expect continued near-term volatility as revenue trends and integration outcomes play out
Similar Companies in Healthcare
Other companies in the same sector with AI ratings